In their recent article, Romero-Corral et al.1 report on obesity as a factor of risk assessment in individuals with and without cardiovascular disease. They suggest that the “obesity paradox” is merely based on the inadequacy of BMI to differentiate between lean and fat mass. Against the background of obesity, the authors perceive adipose tissue as a plain cardiovascular risk factor and view lean mass as the protective element. It is argued that the favourable impact of elevated BMI results from the beneficial effects of lean tissue overriding the adverse effects of excess body fat. Romero-Corral et al. assume that accurate fat tissue assessment (such as dual-energy X-ray absorptiometry [DEXA]) may prove its nocuous impact. In chronic diseases, however, we propose to consider a more differentiated view on adipose tissue.
Fat tissue is the most important energy storage of the body providing over 80% of all energy reserves.2 Chronic diseases, such as chronic heart failure (CHF), are characterized by an accelerated downward spiral of anabolic/catabolic imbalance and symptomatic status that leads to a particularly poor prognosis.3 Adipose tissue buffers its detrimental impact.
We have recently presented data from a study in 511 CHF patients in which body composition was assessed using DEXA for prognostic reasons.4 Notably, total fat mass (16.9 ± 7.9 kg vs 20.4 ± 8.2 kg, P <0.0001) and percent fat (23 ± 7% vs 26 ± 8%, P <0.0001) were significantly lower in non-survivors compared to survivors (median follow-up 29 months, 110 fatal events). In contrast, lean mass and fat distribution (i.e. ratio between central and peripheral fat) did not differ between the two groups. Total fat mass (hazard ratio [HR] 0.95, 95% CI 0.92–0.98; P = 0.0004) and percent fat (HR 0.94, 95% CI 0.91–0.97; P <0.0001) predicted better survival independently of New York Heart Association class, exercise capacity, and BMI. Quartiles of percent fat showed a linear stepwise decrease for risk with the best survival in quartile IV (HR 0.35, 95% CI 0.19–0.64; P = 0.0056) compared to the first quartile. Lean mass did not predict mortality.
Similar results were obtained by Kalantar-Zadeh et al.5 in 535 patients with chronic kidney disease receiving maintenance haemodialysis. In these subjects, body fat was assessed via near infrared interactance. After multivariate adjustment for demographics, surrogates for muscle mass and inflammation, the risk of death was 4 times higher for patients with a body fat <12% (n = 46), compared to a body fat content between 24% and 36% (n = 199) (HR 4.01, 95% CI 1.61–9.99; P = 0.003). Fat loss of ≤1%, re-assessed after 6 months, was associated with a doubled mortality risk compared to weight-gainers (≥1%, P = 0.04).
It remains undisputed that increasing body weight worsens cardiovascular and metabolic status in young and middle-aged subjects without co-morbidities. Excess adipose tissue, however, has been shown to improve outcomes in patients with already established chronic disease. Obesity represents anabolic dominance; hence, catabolic stimuli need to be much stronger to shift the metabolic balance towards catabolism. Furthermore, the eventually started catabolic spiral is protracted by an expanded access to energy deposits.
References
Romero-Corral A et al. (2008) Differentiating between body fat and lean mass—how should we measure obesity? Nat Clin Pract Endocrinol Metab 4: 322–323
Pichard C and Kyle UG (1998) Body composition measurements during wasting diseases. Curr Opin Clin Nutr Metab Care 1: 357–361
Anker SD et al. (2004) Cardiac cachexia. Ann Med 36: 518–529
Cicoira M et al. (2004) Body composition and prognosis in 511 chronic heart failure patients: results from three European centers. Eur J Heart Fail 25 (Suppl 3): 356
Kalantar-Zadeh K et al. (2006) Associations of body fat and its changes over time with quality of life and prospective mortality in hemodialysis patients. Am J Clin Nutr 83: 202–210
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Szabó, T., von Haehling, S. & Doehner, W. Differentiating between body fat and lean mass—how should we measure obesity?. Nat Rev Endocrinol 4, E1 (2008). https://doi.org/10.1038/ncpendmet0999
Issue Date:
DOI: https://doi.org/10.1038/ncpendmet0999